News|Articles|October 11, 2024
NeurologyLive® Friday 5 — October 11, 2024
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 11, 2024.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Challenges and Opportunities Bringing Lecanemab to Neurology Community Clinics
In our latest fall digital issue, a group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.
2: Advancing Multiple Sclerosis Diagnosis With the 2024 Criteria Revision: Xavier Montalban, MD, PhD
The chair of neurology at Hospital Universitari Vall d’Hebron talked about the revision of the MS diagnostic criteria that will integrate new evidence, biological markers, and advanced MRI findings to enable earlier and more precise diagnoses.
3: Exploring the Impact of Circadian Rhythms on Glial Function and Alzheimer Disease
Erik Musiek, MD, PhD, a professor of neurology at Washington University in St. Louis, provided clinical insight on a presentation from ANA 2024 highlighting the intricate relationship between circadian rhythms, glial activation, and neuroinflammation in Alzheimer disease.
4: NeuroVoices: Joseph Kuchling, MD, on Bridging Gaps in Autoimmune Condition Overlap With New MS Diagnostic Criteria
In our latest Q&A for NeuroVoices, the postdoctoral research assistant at Charité University Berlin discussed how the new diagnostic criteria for multiple sclerosis could offer earlier detection, especially in those with overlapping autoimmune conditions, through advanced imaging markers.
5: Key Updates in SMA Diagnosis: What Clinicians Should Know
In our latest Roundtable Discussion video series episode, a panel of experts delves into the latest updates on spinal muscular atrophy diagnosis, focusing on the critical role of newborn screening, early intervention, and evolving classification methods for improved patient outcomes.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
NeurologyLive® Friday 5 — September 12, 2025September 12th 2025
Expanding the Alzheimer Drug Development PipelineSeptember 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
Expanding the Alzheimer Drug Development Pipeline
2
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
3
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
4
Patient-Reported Study Identifies Common Symptoms and Timing During Migraine Prodrome
5
